Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05261139 · ClinicalTrials.gov registry record · Phase 3
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
A Phase 3 study of COVID-19, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 160
- Enrollment target
- 20
- Study locations
NCT05261139 is a Phase 3 study of COVID-19 that is actively recruiting participants, run by Pfizer. The registered enrollment target is 160 participants, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT05261139, a Phase 3 study of COVID-19, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 160 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this clinical trial is to learn about the safety, pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and eliminated from your body after you take it), and efficacy (how well a study treatment works in the study) of the study medicine (called nirmatrelvir/ritonavir) for potential treatment of coronavirus disease 2019 (COVID-19). The study medicine will be given to patients under 18 years of age with COVID-19 that are not hospitalized but are at risk for severe disease.
Conditions Studied
Interventions
- DRUG nirmatrelvir
- DRUG ritonavir
Study Locations (20)
California
- Children's Hospital Los Angeles - Los Angeles
- Kaiser Permanente - Los Angeles
- UCLA David Geffen School of Medicine - Los Angeles
- UCLA - Los Angeles
Georgia
- Children's Healthcare of Atlanta - Arthur M. Blank Hospital - Atlanta
- Rophe Adult and Pediatric Medicine/SKYCRNG - Union City
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
- University of Chicago Medical Center - Chicago
Massachusetts
- Boston Medical Center - Boston
- University of Massachusetts Chan Medical School - Worcester
Missouri
- St. Louis Children's Hospital - St Louis
- Washington University School of Medicine - St Louis
Arizona
- Phoenix Children's Hospital - Phoenix
District of Columbia
- Children's National Medical Center - Washington D.C.
Florida
- Life Spring Research Foundation - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2022-03-07 |
| Est. Completion | 2026-07-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05261139
The ClinicalTrials.gov registry entry for NCT05261139 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which nirmatrelvir is the first listed.
NCT05261139 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Georgia, Illinois.
Frequently Asked Questions
What is clinical trial NCT05261139 about?
NCT05261139 is a clinical study titled "EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease". The purpose of this clinical trial is to learn about the safety, pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and eliminated from your body after you take it), and efficacy (how well a study treatment works in the study) of the study medicine (called nirmatrelvir/ri...
What is the current status of trial NCT05261139?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 160 participants. The study started on 2022-03-07. Estimated completion is 2026-07-30.
What conditions does trial NCT05261139 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT05261139?
The interventions under investigation include: nirmatrelvir (DRUG), ritonavir (DRUG).
Who is sponsoring clinical trial NCT05261139?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05261139 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
RECRUITING · Phase 3
-
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
RECRUITING · Phase 3
-
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
RECRUITING · Phase 3
-
A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Immunogenicity of NVX-CoV2705
ACTIVE NOT RECRUITING · Phase 3
-
Study of VYD2311 for the Prevention of COVID-19
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.